| abstract |
Compounds that inhibit the kinase activity of double leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and trauma to central and peripheral nervous system neurons (eg, stroke, traumatic brain injury, spinal cord injury) Caused neurological or chronic neurodegenerative conditions (eg Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy Body disease, Kennedy disease, and other related conditions), neuropathy resulting from nerve injury (chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and related conditions), and cognitive impairment resulting from pharmacological intervention ( For example, methods for treating DLK-mediated diseases such as neurological diseases caused by chemotherapy-induced cognitive impairment (also known as chemobrain) It disclosed herein. |